Vaxcyte, Inc. PCVX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s total equity?
- Vaxcyte, Inc. (PCVX) reported total equity of $3B in Q1 2026.
- How has Vaxcyte, Inc.'s total equity changed year-over-year?
- Vaxcyte, Inc.'s total equity decreased by 6.4% year-over-year, from $3.2B to $3B.
- What is the long-term trend for Vaxcyte, Inc.'s total equity?
- Over 5 years (2020 to 2025), Vaxcyte, Inc.'s total equity has grown at a 50.7% compound annual growth rate (CAGR), from $345.84M to $2.69B.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.